Fundz

Watching Medifast, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

Medifast, Inc.

Filed: Jul 17, 2026CIK: 0000910329
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Medifast, Inc. announced on July 17, 2026, that its wholly-owned subsidiary OPTAVIA is being rebranded to Trilivy to operate as a comprehensive metabolic health system. This strategic rebranding aims to better align the brand with its health and wellness mission and reflects an evolution in the company's market approach.

Key Takeaways

OPTAVIA subsidiary is being rebranded to Trilivy effective July 17, 2026

The new brand will position the company as a comprehensive metabolic health system

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 17, 2026
Item7.01
CategoryReg FD Disclosure
CIK0000910329
Accession #med-20260717
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
product launch

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings

Medifast, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.